VICL Profile
Vical Incorporated (VICL) was a biopharmaceutical company that focused on the development of DNA-based vaccines and gene therapies. The company was headquartered in San Diego, California, and was founded in 1987. Vical's stock was listed on NASDAQ until it was acquired by Brickell Biotech, Inc. in December 2020.
Vical's lead product candidate was a DNA-based vaccine for cytomegalovirus (CMV), a common virus that can cause serious complications in people with weakened immune systems. Vical's CMV vaccine was in clinical development for several years and showed promising results in early-stage trials. However, in 2017, the company announced that its phase 3 clinical trial did not meet its primary endpoint, and Vical discontinued development of the vaccine.
In addition to its CMV vaccine, Vical had several other product candidates in development, including gene therapies for rare genetic diseases and cancer immunotherapies. However, many of these programs were in early-stage development and had not yet advanced to clinical trials.
In December 2020, Brickell Biotech, Inc. acquired Vical in an all-stock transaction valued at approximately $11 million. Brickell is a clinical-stage biopharmaceutical company that focuses on the development of dermatological therapies. The acquisition of Vical expanded Brickell's pipeline to include gene therapy candidates for rare genetic diseases.
As a result of the acquisition, Vical's stock was delisted from NASDAQ and is no longer publicly traded. The company now operates as a subsidiary of Brickell Biotech.
|
